1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies

Report Details
Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 309-page report provides 260 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and therapies
How will submarkets perform to 2025? Our study forecasts revenues in the following asthma and COPD therapies submarkets:
- Combination drugs
- Anti-inflammatory drugs
- Corticosteroids
- Anti-Leukotrienes
- Monoclonal antibodies
- Other anti-inflammatories
- Bronchodilator monotherapy
- Short-acting beta2-agonist (SABAs)
- Long-acting beta2-agonist (LABAs)
- Anticholinergics

How will individual therapies perform to 2025? Our study forecasts revenues for 27 therapies including 5 promising pipeline candidates:
- Ventolin
- ProAir
- Proventil
- Xopenex
- Foradil
- Serevent
- Arcapta/Onbrez
- Brovana
- Spiriva
- Atrovent
- Eklira/Tudorza/Bretaris
- Flixotide/Flovent
- Pulmicort
- QVAR
- Asmanex
- Singulair
- Xolair
- Cinquil
- Mepolizumab
- Benralizumab
- Lebrikizumab
- Dupilumab
- Advair/Seretide
- Symbicort
- Combivent
- Dulera
- Breo/Relvar Ellipta

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
- US
- Japan
- EU5
- BRIC
- Mexico

Leading companies and potential for market growth
Overall revenue for the Asthma and COPD Therapies market will reach $35.87in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of respiratory diseases globally will drive sales to 2025.

Our work analyses the key companies in the market. See visiongain’s analysis of 7 leading companies, including these:
- GSK
- Boehringer Ingelheim
- AstraZeneca
- Merck
- Novartis
- Roche
- Teva

A company profile gives you the following information where available:
- 10 year revenue forecast for respiratory products with annual growth rates
- Discussion of a company’s activities and outlook
- Analysis of products currently on the market as well as those in the pipeline

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Asthma and COPD Therapies industry?
Our new report discusses issues and events affecting the Asthma and COPD Therapies market. You will find discussions, including qualitative analyses:
- Highly diverse market needing strong knowledge of national markets
- Patent expiry challenging major market players
- Emerging areas of therapies with potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2015-2025 report helps you
In summary, our 309-page report gives you the following knowledge:
- Revenue forecasts to 2025 for the asthma and COPD therapies market – discover the industry’s prospects, finding promising places for investments and revenues
- Revenue forecasts to 2025 for submarkets and leading therapies in each – discover prospects for leading drugs in the following asthma and COPD submarkets: bronchodilator monotherapy (including SABAs, LABAs and anticholinergics), anti-inflammatory drugs (including corticosteroids, anti-leukotrienes and monoclonal antibodies) and combination drugs
- Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5, BRIC and Mexico
- Assessment of 7leading companies – analysis of respiratory revenues, products and pipeline
- Discussion of what stimulates and restrains companies and the market
- Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Table Of Contents

Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
Table of Contents
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: A Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What Is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What Is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report

3. Asthma and COPD Therapies: World Market 2015-2025
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2014
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2015-2025
3.3.1 World Asthma Therapies Market: Sales Forecast 2015-2025
3.3.2 World COPD Therapies Market: Sales Forecast 2015-2025
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2015-2025
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2025?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2015-2025
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?

4. Leading National Markets 2015-2025
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2015-2025
4.2.1 How Will Regional Market Shares Change to 2025?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2015-2025
4.4.1 How Will National Market Shares Change to 2025?
4.5 The US Asthma and COPD Therapies Market 2015-2025
4.5.1 US Asthma and COPD Therapies Market Forecast 2015-2025
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2015-2025
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2015-2025
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2015-2025
4.7.1 German Asthma and COPD Therapies Market Forecast 2015-2025
4.7.2 French Asthma and COPD Therapies Market Forecast 2015-2025
4.7.3 UK Asthma and COPD Therapies Market Forecast 2015-2025
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2015-2025
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2015-2025
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2015
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2015-2025
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2015-2025
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China's Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2014
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2015-2025
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2015-2025
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2015-2025
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico's Agreement for Innovation

5. Bronchodilator Monotherapy Market 2015-2025
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2014
5.2.1 Leading Bronchodilators in 2014
5.3 Bronchodilator Monotherapy: Market Forecast 2015-2025
5.4 How Will Market Shares by Drug Class Change to 2025?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2015-2025
5.5.1 Leading SABAs in 2014
5.5.2 SABAs: Market Forecast 2015-2025
5.5.3 Market Share of Leading SABAs to 2025
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2015-2025
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2015-2025
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2015-2025
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2015-2025
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2015-2025
5.6.1 Leading LABAs in 2014
5.6.2 LABAs: Market Forecast 2015-2025
5.6.3 Market Share of Leading LABAs to 2025
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2015-2025
5.6.5 Brovana (salmeterol, GSK)
5.6.5.1 Brovana: Sales Forecast 2015-2025
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2015-2025
5.6.7 Serevent (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Serevent: Sales Forecast 2015-2025
5.7 The Anticholinergics Market 2015-2025
5.7.1 Leading Anticholinergics in 2014
5.7.2 Anticholinergics: Market Forecast 2015-2025
5.7.3 Market Share of Leading Anticholinergics to 2025
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2015-2025
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2015-2025
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2015-2025

6. Anti-Inflammatory Drugs Market 2015-2025
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2014
6.2.1 Leading Anti-Inflammatory Drugs in 2014
6.3 Anti-Inflammatory Drugs: Market Forecast 2015-2025
6.4 How Will Market Shares by Drug Class Change to 2025?
6.5 The Corticosteroids Market 2015-2025
6.5.1 Leading Corticosteroids in 2014
6.5.2 Corticosteroids: Market Forecast 2015-2025
6.5.3 Market Share of Leading Corticosteroids to 2025
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2015-2025
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2015-2025
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2015-2025
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2015-2025
6.6 The Anti-Leukotrienes Market 2015-2025
6.6.1 Leading Anti-Leukotrienes in 2014
6.6.2 Anti-Leukotrienes: Market Forecast 2015-2025
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2025
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2015-2025
6.7 The Monoclonal Antibodies Market 2015-2025
6.7.1 Monoclonal Antibodies: Market Forecast 2015-2025
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2025
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2015-2025
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2015-2025
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2015-2025
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2015-2025
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2015-2025
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2015-2025

7. Combination Drugs Market 2015-2025
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2014
7.2 Combination Drugs: Market Forecast 2015-2025
7.3 How Will Market Shares by Drug Change to 2025?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2015-2025
7.3.2 Symbicort (budesonide/formoterol fumarate, AstraZeneca)
7.3.2.1 Symbicort: Sales Forecast 2015-2025
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2015-2025
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2015-2025
7.3.5 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK)
7.3.5.1 Breo/Relvar: Sales Forecast 2015-2025
7.4 Recently Launched Combination Drugs

8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2015
8.1.2 Leading Companies: Market Forecast 2015-2025
8.1.3 How Will Leading Companies' Market Shares Change to 2025?
8.2 GSK
8.2.1 GSK: Asthma and COPD Therapies
8.2.2 GSK: Sales Forecast 2015-2025
8.2.3 GSK: Products in Development
8.2.4 GSK: Recent Developments
8.2.4.1 Recently Launched Combination Drugs
8.2.4.2 GSK Divests OTC Products
8.2.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.2.4.4 GSK Presents Data on Eosinophil Levels and COPD
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8.3.2 Boehringer Ingelheim: Sales Forecast 2015-2025
8.3.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.3.4.4 Sale of Roxane Laboratories
8.4 AstraZeneca
8.4.1 AstraZeneca: Asthma and COPD Therapies
8.4.2 AstraZeneca: Sales Forecast 2015-2025
8.4.3 AstraZeneca: Products in Development
8.4.4 AstraZeneca: Recent Developments
8.4.4.1 AstraZeneca Acquires Almirall's Respiratory Portfolio
8.4.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca's Combination Drug Pipeline
8.4.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.4.4.4 AstraZeneca Acquires Right to Actavis' Branded Respiratory Portfolio in US and Canada
8.5 Merck and Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2015-2025
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck's Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2015-2025
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2015-2025
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2015-2025
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax

9. Asthma and COPD Therapies Pipeline Analysis 2015-2025
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.5 Other Asthma and COPD Drugs Pipeline

10. Qualitative Analysis of the Asthma and COPD Therapies Market 2015-2025
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population'
10.3.2 Side-Effects of Drug Classes
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.3.5 Costing Pressures in both Developed and Emerging Markets
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong RandD Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter's Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]

11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King's College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market

12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2014
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2015-2025
12.4 The Future of the Asthma and COPD Therapies Market?
12.4.1 Growth in Anti-Inflammatory and Combination Drugs
12.4.2 Towards Personalised Medicine
12.4.3 Unmet Needs in Asthma and COPD
12.4.4 Strategies for Growth in 2015-2025

13. Glossary

Appendix A

Appendix B

List of Tables
Table 1.1 Asthma and COPD Therapies: Leading National Markets Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014
Table 2.1 Classification of Respiratory Diseases, 2015
Table 2.2 Causes of Asthma, 2015
Table 2.3 Triggers of Asthma, 2015
Table 2.4 Clinical Trial Phases
Table 2.5 Currency Exchange Rates, 2014
Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2014
Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m), 2014
Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 3.6 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2014, 2020 and 2025
Table 4.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2014
Table 4.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2014-2025
Table 4.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2014-2025 (continued)
Table 4.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2014, 2020 and 2025
Table 4.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2014
Table 4.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
Table 4.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025 (continued)
Table 4.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2014, 2020 and 2025
Table 4.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
Table 4.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2014-2025
Table 4.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 4.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2014
Table 5.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2014
Table 5.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
Table 5.4 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2025
Table 5.5 Leading SABAs: Revenues ($m) and Market Shares (%), 2014
Table 5.6 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 5.7 SABAs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 5.8 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.9 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.10 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.11 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.12 Leading LABAs: Revenues ($m) and Market Shares (%), 2014
Table 5.13 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 5.14 LABAs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 5.15 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.16 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.17 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.18 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.20 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2014
Table 5.21 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 5.22 Anticholinergics Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 5.23 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 5.24 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2014-2024
Table 5.25 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2014
Table 6.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2014
Table 6.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2014-2025
Table 6.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2020 and 2025
Table 6.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2014
Table 6.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 6.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025 (continued)
Table 6.7 Corticosteroids Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 6.8 GSK: Flixotide/Flovent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2014
Table 6.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 6.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 6.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 6.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 6.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.19 Teva: Cinquil Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.20 GSK: Mepolizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 6.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.1 Leading Combination Drugs: Revenues ($m) and Market Shares (%), 2014
Table 7.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 7.3 Combination Drugs Market: Market Shares (%) by Drug, 2014, 2020 and 2025
Table 7.4 GSK: Advair/Seretide Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 7.8 GSK: Breo/Relvar Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2014
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025
Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2014-2025 (continued)
Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2020 and 2025
Table 8.4 AstraZeneca: Overview, 2014
Table 8.5 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.6 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 8.7 AstraZeneca: Asthma and COPD Therapies Pipeline, 2015
Table 8.8 Boehringer Ingelheim: Overview, 2014
Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2014-2025
Table 8.11 GSK: Overview, 2014
Table 8.12 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.13 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
Table 8.14 GSK: Asthma and COPD Therapies Pipeline, 2015
Table 8.15 Merck: Overview, 2014
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
Table 8.18 Novartis: Overview, 2014
Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2015
Table 8.22 Roche: Overview, 2014
Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
Table 8.24 Teva: Overview, 2014
Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2014
Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%),CAGR (%) by Drug, 2014-2025
Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2015
Table 9.1 Asthma and COPD Drugs Pipeline by Segment, 2015
Table 9.2 Bronchodilators Pipeline: Phase 3 Drugs, 2015
Table 9.3 Anti-Inflammatory Drugs Pipeline: Phase 3 Drugs, 2015
Table 9.4 Combination Drugs Pipeline: Phase 3 Drugs, 2015
Table 9.5 Other Asthma and COPD Drugs Pipeline, 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

Download Unlimited Documents from Trusted Public Sources

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

Opioid Market in the US

  • December 2016
    14 pages
  • Opioid  

  • United States  

View report >

Therapy Market in Denmark - Forecast

  • December 2016
    12 pages
  • Therapy  

  • Denmark  

View report >

Related Market Segments :

Therapy
Asthma

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.